Clinically tested botanical
therapeutics for a life without cancer

CANCER:
Common, Expensive, Recurring

40%

of Americans will be diagnosed with cancer
at least once. 18 million cancer survivors (US)
rising to ~25 million by 2040.

45%

of cancer patients experienced treatment delays due to drug shortages.

90%

of those cancers may recur after treatment. 85% ovarian cancer recurrence within 24 months.

Currently, little-to-no cancer drugs target/prevent cancer returning.

Our Brands

Prostate and Ovarian Cancer Markets

Total Accessible Market

18 million cancer survivors currently in the US, projected to rise to 22.5 million by 2032.

Serviceable
Available Market

Ovarian cancer:

  • 19,600 new diagnoses/year, 235,000 survivors (USA).

Prostate Cancer:

  • ~260,000 new diagnoses/year, 3.5 million survivors (USA).

Serviceable Obtainable Market

Conservative assumption 10% market within 4 years:

  • Prostate survivor market:

    • 350,000 patients. Each year 26,000 new patients.

  • Ovarian survivor market:

    • 23,500 patients. Each year 2,000 new patients.

Virtually No Competition

Prostate Cancer

Very few drugs for post-chemotherapy/treatment to aid in cancer remission.

Xtandi® (Enzalutamide)

  • Patented drug produced by Pfizer and Astellas Pharma.

  • Use: Nonsteroidal antiandrogen used in conjunction with castration for patients with rising PSA (prostate-specific antigen) levels.

  • Side Effects: asthenia (weakness),
    back pain, seizures (rare).

  • Patient cost per year: $160-180,000
    ($113 per capsule).

  • Combined revenue: >$2 billion/year.

ArtemiCafé™️ Decaf

  • Use (targeted): e.g. Prostate cancer – decrease rising PSA for patients with recurrence of prostate cancer.

  • Side Effects: no adverse effects observed in
    Phase I clinical trial.

  • Patient cost per year: $3,600 ($300 per month).